Suitable for use to measure free Rituximab in patient samples.
Recommended antibody pair for pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB242 - CABT-ZB243
Recommended Working Concentration: 0.01-0.1 μg/ml
Summary
Specifications
Antibody Isotype
IgG1
Clone
28C7
Immunogen
Rituximab
Conjugate
Unconjugated
Applications
Application Notes
Suitable for use in PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB242 - CABT-ZB243 Recommended Working Concentration: 0.01-0.1 μg/ml
General Notes
We recommend the following antibody pair to develop a pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB242 - CABT-ZB243 CABT-ZB243 is recommended for use as a detection antibody when paired with CABT-ZB242 as a capture antibody. Rituximab (Rituxan) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of hematological cancers and autoimmune diseases. When Rituximab binds to CD20 on the surface of normal and malignant B cells, natural killer (NK) cells is activated to destroy these B cells. It is therefore used to treat diseases with too many B cells, overactive B cells, or dysfunctional B cells.
Target
Alternative Names
Mouse monoclonal antibody to Rituxan; RITUXIMAB; Anti-CD20 antibody; MabThera
Citations
Publication ()
Have you cited CABT-ZB243 in a publication? Let us know and earn a reward for your research.
My Review for Mouse Anti-Rituximab monoclonal antibody, clone 28C7
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
